Cyberonics, Inc. Announces Third Quarter Results Conference Call

Apr 23, 2001, 01:00 ET from Cyberonics, Inc.

    HOUSTON, April 23 /PRNewswire Interactive News Release/ --
 Cyberonics, Inc. (Nasdaq:   CYBX) today announced its intention to release third
 quarter financial results for the fiscal year ending April 27, 2001 after the
 close of the market at 4:00 p.m. EDT on Wednesday, April 25, 2001.  The
 Company has scheduled a simultaneous conference call and Internet presentation
 for 4:30 p.m. EDT on Wednesday, April 25, 2001 to discuss the results for the
 third quarter ended March 31, 2001.
     Two separate phone lines are necessary to access the conference call and
 Internet presentation.  The conference call may be accessed by dialing
 800-709-3797 (if dialing from within the U.S.) or 706-679-3035 (if dialing
 from outside the U.S.).  The conference ID is 792498; the leader is Skip
 Cummins.  You may access the Cyberonics Internet presentation site via the
 PresentPLUS Gateway address
 http://www.presentplus.com/conference/gateway.html.  To test your system in
 advance, take the instant system check by clicking on the PresentPLUS Gateway
 link above, then select Browser Check from the available options.  If you
 encounter difficulty, support solutions will be provided, or you may call
 PresentPLUS toll-free at 888-966-8686 or email support@presentplus.com with
 your telephone number for an immediate call back.  Once proper compatibility
 is confirmed, the presentation site can be accessed 10 minutes prior to the
 scheduled start, beginning at 4:20 p.m. EDT on Wednesday, April 25, 2001.
 Click on the link http://www.presentplus.com/conference/gateway.html, then
 click on "Attendee Login" from the available options.  The event name is
 ppcyberonics.
     Cyberonics, Inc. (www.cyberonics.com) was founded in 1987 to design,
 develop and market medical devices for the treatment of epilepsy and other
 debilitating disorders using a unique therapy, vagus nerve stimulation.  The
 Company's initial target market is epilepsy, the world's second most prevalent
 neurological disorder, which is characterized by recurrent seizures.  Vagus
 Nerve Stimulation (VNS(TM)) with the Cyberonics NeuroCybernetic Prosthesis
 (NCP(R)) System was approved by the FDA on July 16, 1997 for use as an
 adjunctive therapy in reducing the frequency of seizures in adults and
 adolescents over 12 years of age with medically refractory partial onset
 seizures.  In addition to the U.S., the NCP System is currently approved for
 sale as a treatment for epilepsy in all the member countries of the European
 Union, Canada, Australia and other markets.  VNS delivered by the NCP System
 is at various levels of investigational clinical study as a potential
 treatment for depression, obesity and Alzheimer's disease.  Earlier this year,
 Cyberonics received CE Mark Approval to sell VNS in the member countries of
 the European Union and Canada as a treatment for patients with treatment
 resistant or recurrent depression.
     NCP is a registered trademark of Cyberonics, Inc.  VNS is a trademark of
 Cyberonics, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X58875226
 
 

SOURCE Cyberonics, Inc.
    HOUSTON, April 23 /PRNewswire Interactive News Release/ --
 Cyberonics, Inc. (Nasdaq:   CYBX) today announced its intention to release third
 quarter financial results for the fiscal year ending April 27, 2001 after the
 close of the market at 4:00 p.m. EDT on Wednesday, April 25, 2001.  The
 Company has scheduled a simultaneous conference call and Internet presentation
 for 4:30 p.m. EDT on Wednesday, April 25, 2001 to discuss the results for the
 third quarter ended March 31, 2001.
     Two separate phone lines are necessary to access the conference call and
 Internet presentation.  The conference call may be accessed by dialing
 800-709-3797 (if dialing from within the U.S.) or 706-679-3035 (if dialing
 from outside the U.S.).  The conference ID is 792498; the leader is Skip
 Cummins.  You may access the Cyberonics Internet presentation site via the
 PresentPLUS Gateway address
 http://www.presentplus.com/conference/gateway.html.  To test your system in
 advance, take the instant system check by clicking on the PresentPLUS Gateway
 link above, then select Browser Check from the available options.  If you
 encounter difficulty, support solutions will be provided, or you may call
 PresentPLUS toll-free at 888-966-8686 or email support@presentplus.com with
 your telephone number for an immediate call back.  Once proper compatibility
 is confirmed, the presentation site can be accessed 10 minutes prior to the
 scheduled start, beginning at 4:20 p.m. EDT on Wednesday, April 25, 2001.
 Click on the link http://www.presentplus.com/conference/gateway.html, then
 click on "Attendee Login" from the available options.  The event name is
 ppcyberonics.
     Cyberonics, Inc. (www.cyberonics.com) was founded in 1987 to design,
 develop and market medical devices for the treatment of epilepsy and other
 debilitating disorders using a unique therapy, vagus nerve stimulation.  The
 Company's initial target market is epilepsy, the world's second most prevalent
 neurological disorder, which is characterized by recurrent seizures.  Vagus
 Nerve Stimulation (VNS(TM)) with the Cyberonics NeuroCybernetic Prosthesis
 (NCP(R)) System was approved by the FDA on July 16, 1997 for use as an
 adjunctive therapy in reducing the frequency of seizures in adults and
 adolescents over 12 years of age with medically refractory partial onset
 seizures.  In addition to the U.S., the NCP System is currently approved for
 sale as a treatment for epilepsy in all the member countries of the European
 Union, Canada, Australia and other markets.  VNS delivered by the NCP System
 is at various levels of investigational clinical study as a potential
 treatment for depression, obesity and Alzheimer's disease.  Earlier this year,
 Cyberonics received CE Mark Approval to sell VNS in the member countries of
 the European Union and Canada as a treatment for patients with treatment
 resistant or recurrent depression.
     NCP is a registered trademark of Cyberonics, Inc.  VNS is a trademark of
 Cyberonics, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X58875226
 
 SOURCE  Cyberonics, Inc.